Compare Genuine Parts Company (GPC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Revvity Inc — how do they compare? Genuine Parts Company trades at $127.54 (market cap $17.67B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: Genuine Parts Company and Revvity Inc are close in size by market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Revvity Inc for 12 Days on average.
| GPC | RVTY | |
|---|---|---|
Market Cap | $17.67B | $16.98B |
Volume | 1,079,458 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $157.36 |
52-Week Low | $92.47 | $82.26 |
Typical Hold Time | 75 Days | 12 Days |
Enterprise Value | $23.76B | $19.30B |
Dividend Yield | 3.32% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $127.16, up 1.4% today, near its pivot point of $127 with technical indicators showing a bullish trend. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20. Revenue growth is steady, but net income margins have compressed significantly to 0.13% in 2025. Analysts maintain a consensus price target of $145.75, with 43% recommending Buy. Key developments include the planned spinoff of its industrial unit, Motion, scheduled for Q1 2027.
The outlook for GPC is cautiously optimistic, driven by the potential value unlock from the corporate split and its position in the resilient automotive aftermarket. However, thin profit margins and rising debt levels pose risks. The stock offers a dividend yield supported by its Dividend King status, but investors should weigh execution risks around the separation against the prospect of segment-specific reratings.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
